Nutra Pharma Corp.
NPHC · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.11 | -0.02 |
| FCF Yield | -40.13% | -12.33% | -11.15% | -31.58% |
| EV / EBITDA | -5.62 | -1.80 | -35.86 | -1.77 |
| Quality | ||||
| ROIC | 49.86% | 4.01% | 14.33% | 9.13% |
| Gross Margin | 56.82% | 8.66% | 28.74% | 33.25% |
| Cash Conversion Ratio | -0.09 | 0.13 | 1.14 | 0.11 |
| Growth | ||||
| Revenue 3-Year CAGR | 103.64% | -2.17% | -26.48% | -4.80% |
| Free Cash Flow Growth | 54.00% | -101.76% | -18.87% | 25.63% |
| Safety | ||||
| Net Debt / EBITDA | -4.54 | -0.65 | -14.17 | -1.39 |
| Interest Coverage | -2.41 | -3.87 | -2.75 | -4.46 |
| Efficiency | ||||
| Inventory Turnover | 7.93 | 2.85 | 7.02 | 8.52 |
| Cash Conversion Cycle | -1,338.76 | -1,405.74 | -5,582.40 | -2,898.77 |